LRMR - Larimar Therapeutics, Inc.

1.88
0.170   9.043%

Share volume: 2,205,983
Last Updated: 04-09-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.07%

PREVIOUS CLOSE
CHG
CHG%
$1.71
0.17
0.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 0%
Dept financing 3%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.53%
1 Month
-34.72%
3 Months
-48.63%
6 Months
-72.27%
1 Year
-72.51%
2 Year
-57.75%
Key data
Stock price
$1.88
P/E Ratio 
0.00
DAY RANGE
$1.61 - $1.92
EPS 
-$1.32
52 WEEK RANGE
$1.61 - $11.20
52 WEEK CHANGE
-$73.96
MARKET CAP 
246.932 M
YIELD 
N/A
SHARES OUTSTANDING 
63.807 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.73
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,076,572
AVERAGE 30 VOLUME 
$1,095,339
Company detail
CEO: Carole S. Ben-Maimon
Region: US
Website: larimartx.com
Employees: 30
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia.

Recent news
loading